Last updated: February 15, 2026
What Is the Product Chemistry and Approved Indication?
NDC 62135-0618 refers to a prescription drug product with the following characteristics:
- Active Substance: Bempedoic acid (170 mg)
- Formulation: Tablet
- Indication: Approved by the FDA for the reduction of LDL cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia, as an adjunct to diet and maximally tolerated statin therapy.
Note: This NDC code specifically covers the branded product, Nexletol, marketed by Esperion Therapeutics.
What is the Current Market Landscape and Competition?
Key Competitors:
| Product Name |
Active Ingredient |
Marketed By |
Approval Year |
Indication |
| Atorvastatin (Lipitor) |
Atorvastatin |
Pfizer |
1996 |
LDL cholesterol reduction |
| Rosuvastatin (Crestor) |
Rosuvastatin |
AstraZeneca |
2003 |
Lipid management |
| Ezetimibe (Zetia) |
Ezetimibe |
Merck |
2002 |
LDL reduction, often combined with statins |
| Inclisiran (Leqvio) |
Inclisiran |
Novartis |
2020 |
PCSK9 inhibitor, LDL reduction |
| Evolocumab (Repatha) |
Evolocumab |
Amgen |
2015 |
PCSK9 inhibitor |
Market Size & Growth:
- Total lipid-modifying agent market (2022): Approximately $20 billion annually.
- Bempedoic acid (Nexletol) sales (2022): Reported around $400 million, indicating rapid growth following launch in 2020.
- Projected CAGR (2023-2030): 15% driven by increased awareness and expanding indications.
What Are the Price and Reimbursement Trends?
Current Pricing:
- Wholesale Acquisition Cost (WAC): Estimated at $470 – $510 for a 30-tablet supply.
- Average Selling Price (ASP): Slightly lower than WAC due to negotiations, estimated around $450 per 30-day supply.
- Patient Out-of-Pocket: Varies based on insurance, with copays ranging from $20 to $50 under most plans.
Reimbursement Landscape:
- Medicare Part D: Covers Nexletol post-authorization, with formulary placement and tier determination affecting patient copays.
- Commercial Insurance: Generally reimburses at similar levels to Medicare, with potential prior authorization requirements.
- Medicaid: Coverage varies by state, often aligned with Medicare/Medicaid formularies.
How Will Market Dynamics Evolve?
Revenue Drivers:
- Label Expansion: Potential approval for additional indications such as familial hypercholesterolemia or statin-intolerant patients could enlarge the market.
- Line of Therapy Placement: Positioned as an adjunct, its uptake depends on clinician preference for combination therapy over monotherapy.
- Physician Adoption: Increased prescribing with growing clinical evidence and guideline inclusion.
Pricing Trends:
- Price erosion expected to moderate as patent exclusivity remains until at least 2029.
- Discounting typical for specialty drugs in this class, with negotiated rebates impacting actual net prices.
Patent and Regulatory Outlook:
- Patent Expiry: Key patents extend to 2029, with potential for patent challenges post-2025.
- Biosimilar or generic entry: Not applicable here, as it's an oral small molecule with no biosimilar pathway.
What Are the Key Opportunities and Risks?
Opportunities:
- Rising prevalence of hyperlipidemia globally.
- Growing demand for non-statin lipid-lowering therapies in statin-intolerant populations.
- Ongoing clinical trials exploring expanded indications.
Risks:
- Competition from generic statins and PCSK9 inhibitors.
- Budget restrictions impacting reimbursement.
- Clinical trial outcomes affecting indications and market share.
Price Projection Summary (2023–2028)
| Year |
Price Range (per 30-day supply) |
Commentary |
| 2023 |
$450–$510 |
Stabilization post-launch, minor discounts |
| 2024 |
$440–$500 |
Slight price erosion, stable demand |
| 2025 |
$430–$490 |
Patent protections and new clinical data support stability |
| 2026 |
$420–$480 |
Market saturation, potential competition |
| 2028 |
$410–$470 |
Competitive pressures increase, price decline slows |
Key Takeaways
- NDC 62135-0618 (Nexletol) operates in a rapidly growing lipid-modifying drug market valued at $20 billion annually.
- Sales have surpassed $400 million with expectations to exceed $1 billion by 2028, contingent on expanded indications.
- Current prices are around $450, with modest declines projected over five years due to competition and patent stability.
- The competitive landscape remains dynamic, with ongoing developments in PCSK9 inhibitors and other lipid-lowering therapies.
- Market growth hinges on clinical adoption, payer strategies, and regulatory milestones.
Frequently Asked Questions
1. How does Nexletol compare price-wise to statins?
Nexletol's monthly cost (~$450) exceeds generic statins (~$10–$20), but it targets patients intolerant or unresponsive to statins.
2. What are the key factors influencing future pricing?
Patent duration, clinical guideline adoption, competition from generics or biosimilars, and payer negotiations.
3. Is there potential for expanding Nexletol’s indications?
Yes, ongoing trials aim at familial hypercholesterolemia and statin intolerance, which could extend market reach.
4. How is reimbursement affecting sales?
Coverage varies; higher copays or prior authorization can limit prescriptions but generally support continued sales growth.
5. What are the risks of generic entry?
Patent expiry in 2029 limits immediate generic competition, but post-expiry, pricing could decline significantly.
References
- [1] IQVIA Pharmacy Market Insights, 2022.
- [2] FDA Drug Approvals and Labeling, 2020.
- [3] Esperion Therapeutics financial reports, 2022.
- [4] MarketWatch, "Lipid-Lowering Drugs Market Size," 2022.
- [5] EvaluatePharma, "Pharmaceutical Market Forecasts," 2023.
Note: All price and market estimates are indicative and based on current data; actual figures may vary with market conditions and regulatory updates.
